Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180981 | 1.00 | UTS2R (0.52) | UTS2RCTSKTAS1R3TAS1R1CTSB | |
| SCHEMBL4181100 | 1.00 | UTS2R (0.52) | UTS2RCTSKTAS1R3TAS1R1CTSB | |
| SCHEMBL4185654 | 1.00 | UTS2R (0.52) | UTS2RCTSKTAS1R3TAS1R1CTSB | |
| SCHEMBL4178416 | 0.94 | UTS2R (0.51) | UTS2RCTSKTAS1R3TAS1R1CTSB | |
| SCHEMBL4194752 | 0.92 | CTSK (0.51) | UTS2RCTSKTAS1R3TAS1R1CTSB | |
| SCHEMBL4185754 | 0.90 | CTSK (0.46) | UTS2RCTSKCTSBCTSSTACR2 | |
| SCHEMBL4179196 | 0.88 | TACR2 (0.44) | UTS2RCTSKCTSBCTSSTACR2 | |
| SCHEMBL4185942 | 0.88 | CTSK (0.48) | UTS2RCTSKTAS1R3TAS1R1CTSB | |
| SCHEMBL4183416 | 0.88 | CTSK (0.48) | UTS2RCTSKTAS1R3TAS1R1CTSB | |
| SCHEMBL4185931 | 0.88 | TRPV4 (0.60) | UTS2RCTSKTAS1R3TAS1R1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | claimed |
| EP-1869026-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105475-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
| EP-1869026-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105475-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | TRPV4, TRPC4, TRPV1 | UTS2R 391/4885CTSK 1738/4885TAS1R3 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.